What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
The new mantra for delivering optimal cancer treatment is "personalized care." This extends beyond the holistic to using germline and somatic tumoral mutations to link a specific therapy to some prognostic or predictive factor which defines a particularly responsive patient subgroup who might benefit most from treatment. Furthermore, inherited polymorphisms have the potential to greatly modulate the side effects of treatment, especially for chemotherapy which has a notoriously narrow therapeutic window.
Al-Salama
Haitham M
HM
Sidra Medical and Research Centre, Qatar Foundation, Doha, Qatar.
Johnstone
Elaine C
EC
Kerr
David James
DJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D055106:Genome-Wide Association Study; D042822:Genomic Instability / Q000235:genetics; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods; D057285:Precision Medicine / Q000379:methods
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor